GENE ONLINE|News &
Current Challenges and Future Opportunities of Artificial RNA Editing – An Interview with Professor Toshifumi Tsukahara
With two COVID-19 vaccines gaining emergency use approvals, mRNA technology has come into focus over the past year. RNA technology encompasses a wide range of modalities and RNA editing is one among them. Although the technique is still being perfected and hasn’t become clinically viable, its high efficiency and safety over DNA editing is expected to make a splash in the near future.
We interviewed Professor Toshifumi Tsukahara, an expert in RNA editing to know more about the current challenges and future opportunities in the field.
We interviewed Professor Toshifumi Tsukahara, an expert in RNA editing to know more about the current challenges and future opportunities in the field.
It's free! Log in now to read
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
